Sign inSubmit
ArticleMetrics
Research Article · Open access · Published 3 August 2011

Tolemerase Reverse Transcriptase Gene Expression as a Tumor Marker for Hepatocellular Carcinoma

M. Magdi Atta1, Naglaa Al-Toukhy1, Omnia Al-Said1, Adel F. Al-Kholy1, Naglaa Fathy Al Husseini1 & Amal Abou El-Fadle1

American Journal of Biochemistry and Biotechnology, Volume 7, Issue 2, pp. 55–62 · doi.org/10.3844/ajbbsp.2011.55.62

7,905 accesses5,298 downloads1 citations (Crossref)Metrics
Cite Check for updates

Abstract

Problem statement: Hepatocellular carcinoma will emerge as a major form of malignancy in the coming decades. The continuing high incidence of hepatocellular carcinoma, suggests that this disease will continue to represent a global health problem far into the future. Different genes encode for the various components of the human telomerase complex. These components include the human Telomerase RNA Component (hTERC) and the Telomerase Catalytic Subunit (hTERT). Correlation between Telomerase Reverse Transcriptase (hTERT) expression and telomerase activity has been reported in cancer patients. This work aimed to clarify the significance of human Telomerase Reverse Transcriptase (hTERT mRNA) as a potential molecular tumor marker for Hepatocellular Carcinoma (HCC). Approach: The current study included 25 patients of hepatocellular carcinoma (HCC), 30 patients with liver cirrhosis and 25 age and sex matched individuals with normal laboratory and Image findings as a control group. hTERT mRNA was measured in plasma by Real time PCR in all patients samples in comparison with normal healthy controls. Results: The expression of hTERT mRNA by relative unit was 129.10±27.6 with range (67.72-69.6) Vs 5245.87±2382.48 (2053-12232.90) Vs 92782.76±16158 (61783.25-118596.47) for control Vs cirrhosis Vs HCC group respectively. The hTERT expression was significantly with 699 and 33 fold increase in HCC and cirrhosis groups correspondingly when compared to that of controls p<0.05. Conclusion: It was suggested that this procedure was highly discriminating between healthy subjects and cancer patients and strongly support the idea that a valuable diagnostic test for cancer might be developed using this genetic marker in plasma. However it needs to be combined with other markers in future studies to be more specific for liver cancer.

Licence and reuse

Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.

How to reuse this article

Responses (0)

Have a comment on this research? Sign in to respond. Responses are moderated and published with your name and affiliation; the authors are invited to reply. How we use your dataWrite a response

About this article

Cite this article

Atta, M. M., Al-Toukhy, N., Al-Said, O., Al-Kholy, A. F., Al Husseini, N. F. & El-Fadle, A. A. (2011). Tolemerase Reverse Transcriptase Gene Expression as a Tumor Marker for Hepatocellular Carcinoma. American Journal of Biochemistry and Biotechnology, 7(2), 55–62. https://doi.org/10.3844/ajbbsp.2011.55.62

Licence
CC BY 3.0
Issue
Volume 7, Issue 2
Policies
Editorial independenceUse of generative AIData availabilityAppeals and complaints
Version
Version of record
Tolemerase Reverse Transcriptase Gene Expression as a Tumor Marker for Hepatocellular CarcinomaAmerican Journal of Biochemistry and Biotechnology · Volume 7, Issue 2 · pp. 55–62 · CC BY 3.0Download